Editorial
Can molecularly targeted therapy cure patients with resected EGFR mutant NSCLC?
Abstract
In an age of targeted therapies, the promise of eliminating non-targeted and indeed more toxic chemotherapy was considered a given until several trials challenged this assumption.
